Turning to valuation, CrowdStrike shares trade at a forward price-to-sales (P/S) multiple of about 22.5 times analysts' ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Wall Street forecasters expect the stock market to grind higher in 2026 as earnings grow, the Fed cuts rates, and the US ...
Cathie Wood, chief of Ark Investment Management, is making moves in megacap tech stocks. Last month, Wood added to her ...
Now, it’s worth noting Stock Advisor's total average return is 991% — a market-crushing outperformance compared to 195% for ...
Nvidia ( NVDA 0.53%) has been one of the most successful growth stocks of the past decade. The AI chipmaker has rallied by ...
Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...
Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback